[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucoviscidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucoviscidosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617100","prevalence-of-exercise-induced-ventilatory-limitation-and-associated-factors-in-patients-with-cystic-fibrosis-receiving-elexacaftor-tezacaftor-ivacaftor-100617100",false,"NCT07314229","Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor","MUCOLIMEX","Inclusion Criteria:\n\n* Male or female\n* Adult aged 18 or over\n* Suffering from cystic fibrosis\n* Treated at the CRCM in Lille and Créteil\n* Treated by ETI\n* Be covered by social security\n* Be able to understand the requirements of the study, provide written informed consent, and comply with the study's data collection procedures\n\nExclusion Criteria:\n\n* Medical contraindication or inability to perform a stress test according to ERS recommendations\n\n  * Absolute contraindications\n  * Relative contraindications:\n* Exacerbation of the condition in the 4 weeks preceding the V1 visit (27).\n* Pregnant or breastfeeding women\n* Administrative reasons\n* Persons deprived of their liberty\n* Minors or protected adults\n* Persons who have refused or are unable to give informed consent\n* Persons in emergency situations","ALL","18 Years",{"count":19,"type":20},130,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified.\n\nThe main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.",[26,27],"Cystic Fibrosis (CF)","Mucoviscidosis",[29,30,31,32,33,34,35,36],"Cystic fibrosis","physical activity","CFTR modulator treatment","exercise limitation","respiratory physiology","ventilatory limitation","reduction in ventilatory reserve","dynamic distension","RECRUITING","2026-04-21",{"date":40,"type":41},"2026-04-22","ACTUAL",{"date":43,"type":41},"2025-12-17",{"date":45,"type":20},"2027-04-04",{"name":47,"class":48},"University Hospital, Lille","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":5},"100621345","environmental-reservoirs-of-non-tuberculous-mycobacteria-in-cystic-fibrosis-households-a-case-control-study-of-exposure-risk-at-home-100621345","NCT07369414","Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home","NTMecoCF","Inclusion Criteria:\n\n* Confirmed diagnosis of cystic fibrosis (CF)\n* No age restriction (including minors with consent from legal guardians)\n* Written informed consent to participate in the study (or consent provided by a legal guardian for minors)\n* In the case of an NTM infection: diagnosis according to ATS\u002FIDSA criteria and availability of a clinical NTM isolate\n\nExclusion Criteria:\n\n* Lack of capacity to provide informed consent, refusal to participate, or withdrawal of informed consent",{"count":58,"type":20},120,"OBSERVATIONAL","This multicenter, non-interventional case-control study investigates whether household environmental reservoirs, particularly water systems, are associated with non-tuberculous mycobacterial (NTM) infections in people with cystic fibrosis. Environmental samples from the homes of CF patients with and without NTM infection will be analyzed and genetically compared with available clinical isolates, alongside assessment of environmental risk factors, to improve understanding of exposure pathways and inform future prevention strategies.",[26,27,62,63],"Non-Tuberculous Mycobacteria","Mycobacterium Abscessus Infection",[65,66,67,68,69],"Environmental reservoirs","Household water systems","Microbial exposure","Whole-genome sequencing","Environmental risk factors","2026-01-16",{"date":72,"type":41},"2026-01-27",{"date":74,"type":20},"2026-01",{"date":76,"type":20},"2030-12",{"name":78,"class":48},"Research Center Borstel"]